0000899243-22-020086.txt : 20220531
0000899243-22-020086.hdr.sgml : 20220531
20220531100817
ACCESSION NUMBER: 0000899243-22-020086
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220531
FILED AS OF DATE: 20220531
DATE AS OF CHANGE: 20220531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colabuono Peter
CENTRAL INDEX KEY: 0001819620
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 22981031
MAIL ADDRESS:
STREET 1: C/O DECHENG CAPITAL
STREET 2: 3000 SAND HILL ROAD, BUILDING 2, STE 110
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001651431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364813934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 978-503-2124
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-31
1
0001651431
Checkmate Pharmaceuticals, Inc.
CMPI
0001819620
Colabuono Peter
C/O CHECKMATE PHARMACEUTICALS, INC.
245 MAIN STREET, 2ND FLOOR
CAMBRIDGE
MA
02142
1
0
0
0
Stock Option (Right to Buy)
6.27
2022-05-31
4
D
0
10030
D
2031-06-16
Common Stock
10030
0
D
Stock Option (Right to Buy)
10.95
2022-05-31
5
D
0
E
20000
D
2030-11-09
Common Stock
20000
0
D
At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.
At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable.
/s/ Kleem Chaudhary, attorney-in-fact
2022-05-31